Abstract:Polyglutamine diseases comprise a cluster of genetic disorders involving neurodegeneration and movement disabilities. In polyglutamine diseases, the target proteins become aberrated due to polyglutamine repeat formation. These aberrant proteins form the root cause of associated complications. The metabolic regulation during polyglutamine diseases is not well studied and needs more attention. We have brought to light the significance of regulating glutamine metabolism during polyglutamine diseases, which could help in decreasing the neuronal damage associated with excess glutamate and nucleotide generation. Most polyglutamine diseases are accompanied by symptoms that occur due to excess glutamate and nucleotide accumulation. Along with a dysregulated glutamine metabolism, the Nicotinamide adenine dinucleotide (NAD+) levels drop down, and, under these conditions, NAD+ supplementation is the only achievable strategy. NAD+ is a major co-factor in the glutamine metabolic pathway, and it helps in maintaining neuronal homeostasis. Thus, strategies to decrease excess glutamate and nucleotide generation, as well as channelizing glutamine toward the generation of ATP and the maintenance of NAD+ homeostasis, could aid in neuronal health. Along with understanding the metabolic dysregulation that occurs during polyglutamine diseases, we have also focused on potential therapeutic strategies that could provide direct benefits or could restore metabolic homeostasis. Our review will shed light into unique metabolic causes and into ideal therapeutic strategies for treating complications associated with polyglutamine diseases.

Glutaminolysis is a Potential Therapeutic Target for Kidney Diseases

Glutamine metabolism: from proliferating cells to cardiomyocytes

Targeting Glutaminolysis: New Perspectives to Understand Cancer Development and Novel Strategies for Potential Target Therapies

Glutamate Dehydrogenase 1: A Novel Metabolic Target in Inhibiting Acute Myeloid Leukaemia Progression.

Glutamine Metabolism Promotes Renal Fibrosis through Regulation of Mitochondrial Energy Generation and Mitochondrial Fission

Rethinking glutamine metabolism and the regulation of glutamine addiction by oncogenes in cancer

Metabolism of polyamines and kidney disease: A promising therapeutic target

Targeting glutamine metabolism as a therapeutic strategy for cancer

Targeting cellular adaptive responses to glutaminolysis perturbation for cancer therapy

Glutaminolysis: A Hallmark of Cancer Metabolism

Discovery and Development of Small Molecule Modulators Targeting Glutamine Metabolism

Glutamine addiction in tumor cell: oncogene regulation and clinical treatment

The glutamine-alpha-ketoglutarate (AKG) metabolism and its nutritional implications

Exploiting the Achilles' heel of cancer: disrupting glutamine metabolism for effective cancer treatment

Synthetic lethality of glutaminolysis inhibition, autophagy inactivation and asparagine depletion in colon cancer.

T cell metabolic reprogramming in acute kidney injury and protection by glutamine blockade

Targeting GLS1 to cancer therapy through glutamine metabolism

Glutamine metabolism in cancers: Targeting the oxidative homeostasis

Glutaminase - A potential target for cancer treatment

Metabolic reprogramming: Unveiling the therapeutic potential of targeted therapies against kidney disease

Altered Metabolic Signaling and Potential Therapies in Polyglutamine Diseases